NCT06618105
Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 15, 2024
Completion: May 31, 2025